The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Endometrial cancer
Triple negative breast cancer (TNBC) (characterized by HR-negative disease and HER2-negative expression according to American Society of Clinical Oncology (ASCO) - College of American Pathologists guidelines).
Prior treatment with a protein tyrosine kinase 7 (PTK7) antibody-drug conjugate (ADC) with a topoisomerase I inhibitor as payload (prior therapy with a PTK7 ADC with a non-topoisomerase I inhibitor payload OR non-PTK7 ADC with any payload is permitted). Prior topoisomerase I-based ADCs are not allowed in cohorts A2, B1 or B2.
Any serious unresolved toxicities from prior therapy.
Individual with known or suspected history of uncontrolled central nervous system (CNS) metastases.
Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.
Eli Lilly and Company
Lead sponsor